Pierre Fabre
As of the edition of 20 October 2026, Pierre Fabre runs 30 drugs, 11 of them marketed; it is on route A at 1 target and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 4 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Active | 3 |
| Went quiet | 9 |
| Stopped | 6 |
| Status not established | 1 |
| Total | 30 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Vinorelbine | none listed | 8 |
| Propranolol | none listed | 4 |
| Binimetinib | Ends 2033 (patent) | 6 |
| Neratinib | Ends 2030 (patent) | 2 |
| Encorafenib | Ends 2030 (exclusivity) | 3 |
| Milnacipran | none listed | 3 |
| Vinflunine | none listed | 0 |
| Levomilnacipran | Ends 2032 (patent) | 1 |
| Vibegron | Ends 2034 (patent) | 2 |
| Tabelecleucel | none listed | 0 |
| Selenium sulfide | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 6 targets.
All 7 rows on route A or B
In the product7 company-target rows on route A or B; 4 are not shown here, and no score is.
See all 7 targets where Pierre Fabre needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 8 trials led
- Mental health: 6 trials led
- Chemically induced: 5 trials led